Kochi 18 August : Aster Medcity and India Medtronic on Wednesday announced their partnership to create an extensive and sophisticated Deep Brain Stimulation (DBS) program for patients suffering from Parkinson’s disease in India. Parkinson’s disease is a degenerative condition which in its more advanced phases can cause severe disability as a result of the increasing severity of issues with movement, balance, as well as cognitive dysfunction symptoms.
Overall, movement disorders account for about 3-8 percent of neurological disorders in India with an average prevalence rate (CPR) that ranges from 31-45/100,000 over 60 years of age.
In 2016 it was reported that 6.1 million people in the world were suffering from Parkinson’s disease.The incidence in India was calculated at 10% of the burden worldwide which is 5.8 lakhs.
DBS is a form of therapy in which a tiny pacemaker-like device transmits electrical signals through extremely thin wires, also known as aleads’ specific areas in the brain associated with the symptoms.
The launch of the most recent version of the Microelectrode recording system used for DBS procedures, NeuroNav MER system (Alpha Omega) from Medtronic at Aster Medcity Kochi is the first centre in South Asia to introduce this technology the hospital said in an announcement.
“DBS is superior to medical treatments in increasing level of life as well as in decreasing the symptoms of motor impairment of Parkinson’s disease when it is done prior to the disease progressing to an advanced stage.
We are delighted to work with Medtronic in a partnership like this will allow us to introduce the most advanced technologies , such as the NeuroNav MER system in DBS procedures.It will allow the specialists in movement disorders to provide precise data to the neurosurgeon about the precision of the targeting of DBS procedure.” stated Dr.Asha Kishore the Senior Neurologist and Specialist in Movement Disorders, Parkinson and Movement Disorder Centre at Aster Medcity.
“The purpose of the collaboration with Aster is to bring Parkinson’s care up a notch by helping surgeons make faster and more precise treatment decisions with DBS therapy.Clinicians can provide personalized, data-driven therapy that meets the requirements of the modern patients.
With the modern NeuroNav MER technology, targeted localisation which was previously a process that took between 40 to 45 hours, can now be completed in about 10-11 minutes.It is a proof of our commitment to the Medtronic Mission and Parkinson’s patients in India,” said Madan Krishnan, Vice President and Managing Director of Medtronic India.
“Through our collaboration with Medtronic and Medtronic, we are able to offer the most up-to-date innovations in Parkinson’s management.A The technology will improve the quality of patients’ lives and will further improve the outcomes of clinical trials.
We are thrilled to present and provide modern healthcare technologies and therapies for patients in Kerala and throughout the remainder of India,” said Farhan Yasin Regional Director, Aster Hospitals -Oman, Kerala and Oman.
Microelectrode recording (MER) has been regarded as to be the most reliable method in guaranteeing accuracy for the deep brain stimulation process.
The NeuroNav MER system, created by Israeli-based MedTech company Alpha Omega Engineering, is an efficient, field-tested MER system that is utilized clinically in the identification of surgical targets that are used for implant of DBS electrodes to treat of neuropsychiatric and neurological diseases.
NeuroNav provides secure easy, quick, and accurate and precise insertion of electrodes in the brain, while recording activity in the brain as well as stimulating the neural tissue.
rvt/
.
